Is MRD Negativity the End Goal?Why It's Important - HealthTree for Multiple Myeloma
[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Is MRD Negativity the End Goal? Understanding When/Why It's Important

Is MRD Negativity the End Goal? Understanding When/Why It's Important image

Is MRD Negativity the End Goal? Understanding When/Why It's Important

Webinar
event Feb 23, 2023 / 07:00PM - 08:00PM EST
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

Many of you are familiar with the basic concept of MRD, and perhaps some feel the "pressure" to get to MRD negativity. But should all regimens' end goal be to achieve MRD negativity? And if MRD negativity is not achieved with the initial treatment, but the patient is in complete response, should the therapy be adjusted to achieve MRD negativity? This type of question will be answered by myeloma specialist, Dr. Marc Braunstein. Join us as we learn together.

Schedule & Agenda

The panelist Audrey Burton-Bethke
07:00 PM
Introductions
Audrey Burton-Bethke

Audrey introduces the agenda of the event and featured speaker Dr.  Marc Braunstein.

The panelist Marc Braunstein, MD, PhD
07:05 PM
Presentation
Marc Braunstein, MD, PhD

Dr. Marc Braunstein talks about MRD negativity.

Event panelist Audience
07:35 PM
Questions and Answers
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Audrey Burton-Bethke
Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Read Bio
The panelist Marc Braunstein, MD, PhD
Marc Braunstein, MD, PhD

Marc Braunstein, MD, PhD is a board-certified hematologist/oncologist with a long-standing interest in plasma cell disorders. He is a part of the NYU Perlmutter Cancer Center's multiple myeloma and cellular therapy programs and serve as Associate Professor of Medicine at NYU Grossman Long Island School of Medicine where he co-direct the medical school hematology curriculum and also serves as Director of the hematology/oncology fellowship program. His clinical research focus is on the use of novel immunotherapy combinations to treat multiple myeloma. As part of his role, he also focuses on medical education and serves on education committees for the American Society of Hematology and American Society of Clinical Oncology, as well as volunteer committees with the American Society of Clinical Oncology and American College of Physicians. In his free time he volunteers with the Leukemia and Lymphoma Society, spends time with his family, and enjoys playing guitar and mandolin.

Read Bio
HealthTree Connect Icon

Join the Conversation

This event is part of the Lab Values and Testing group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Thanks to our sponsors:
Johnson and Johnson logo
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
Regeneron logo
All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Chronic Myelomonocytic Leukemia Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.